Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury
NCT02255006 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2014-10-02
Summary
Some studies suggest that acupuncture improve flow mediated dilation (FMD) that represents endothelial function, but no study has investigated whether acupuncture protects against ischemia and reperfusion (IR)-induced endothelial dysfunction in humans.
This is a prospective crossover study clinical trial. In the first crossover study, 20 healthy nonsmoking volunteers (25 to 40 years old) will be randomly assigned to acupuncture or control. Endothelium-dependent, FMD of the brachial artery will be measured before and after IR (15 minutes of ischemia at the level of the proximal upper arm followed by 15 minutes of reperfusion). Acupuncture will be performed from 10 minute after ischemia till the end time of reperfusion for 20 minutes. In the second single arm study, 16 volunteers are administered oral 5mg glibenclamide two hours before IR injury (n=8) or selective cox-2 inhibitor celecoxib 200mg twice a day for 5 days to know what mechanism is responsible for acupuncture effect on IR injury. FMD measurements and acupuncture intervention during IR injury are same as above mentioned.
Conditions
- Healthy
Interventions
- DEVICE
-
Active acupuncture
Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
- DEVICE
-
Sham acupuncture
For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group. Volunteers undergo FMD measurement and acupuncture like above methods.
- DRUG
-
Euglucon 5mg
8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
- DRUG
-
Celebrex 200mg
8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
Sponsors & Collaborators
-
Ministry of Health & Welfare, Korea
collaborator OTHER_GOV -
Kyunghee University Medical Center
lead OTHER
Principal Investigators
-
Weon Kim · Kyunghee University Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 25 Years
- Max Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-05-31
- Primary Completion
- 2014-10-31
- Completion
- 2014-12-31
Countries
- South Korea
Study Locations
More Related Trials
-
Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)
NCT00824005 ·Status: COMPLETED ·Phase: PHASE2
-
Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)
NCT00203203 ·Status: COMPLETED ·Phase: PHASE1
-
Cellular & Biocellular Regenerative Therapy in Musculoskeletal Pain, Dysfunction,Degenerative or Inflammatory Disease
NCT03090672 ·Status: UNKNOWN ·Phase: NA
-
Stem Cell Study for Patients With Heart Disease
NCT00221182 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
NCT03840343 ·Status: TERMINATED ·Phase: PHASE1
-
MSC for Occlusive Disease of the Kidney
NCT01840540 ·Status: COMPLETED ·Phase: PHASE1
-
The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis
NCT03383081 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
NCT01556022 ·Status: COMPLETED ·Phase: PHASE2
-
Umbilical Cord Mesenchymal Stem Cells Injection for Peripheral Arterial Disease
NCT02287831 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Effect of Exercise on Stem Cell Mobilization and Heart Function in Patients Undergoing Cardiac Rehabilitation
NCT00053456 ·Status: COMPLETED
-
Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease
NCT01302015 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Autologous, Intracoronary Stem Cell Injections in Total Coronary Artery Occlusions
NCT00365326 ·Status: COMPLETED ·Phase: PHASE1
-
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
NCT03067857 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Cell Therapy in Patients With Chronic Ischemic Heart Disease Undergoing Cardiac Surgery
NCT01267331 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure
NCT01709279 ·Status: UNKNOWN ·Phase: NA
-
SVF (Adipose Tissue Derived MSC) Based Therapy for CKD.
NCT03939741 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Autologous Bone Marrow Derived Mesenchymal Stromal Cells Transplantation(BM-MSC) for Kienbock's Disease
NCT02646007 ·Status: UNKNOWN ·Phase: PHASE1
-
Stem Cell Mobilization to Treat Chest Pain and Shortness of Breath in Patients With Coronary Artery Disease
NCT00043628 ·Status: COMPLETED ·Phase: PHASE2
-
Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)
NCT04776239 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease
NCT01484574 ·Status: COMPLETED ·Phase: PHASE2
-
Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction
NCT03533153 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating
NCT01903044 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Stem Cell Injection to Treat Heart Damage During Open Heart Surgery
NCT01557543 ·Status: TERMINATED ·Phase: PHASE1
-
Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients
NCT01257776 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
NCT05854615 ·Status: RECRUITING ·Phase: PHASE4